+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Disruptive Mood Dysregulation Disorder Market - Global Forecast 2026-2032- Product Image
Disruptive Mood Dysregulation Disorder Market - Global Forecast 2026-2032- Product Image
Sale

Disruptive Mood Dysregulation Disorder Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6160579
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Disruptive Mood Dysregulation Disorder Market is projected to reach USD 1.39 Billion in 2026. It is expected to continue growing at a CAGR of 4.73%, reaching USD 1.85 Billion by 2032.

Disruptive Mood Dysregulation Disorder: Executive Overview

Disruptive Mood Dysregulation Disorder (DMDD) is a childhood and adolescent mental health condition characterized by persistent irritability, frequent severe temper outbursts, and impairment across home, school, and social settings. Recognized in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), DMDD is differentiated from episodic mood disorders by its chronic pattern of irritability. Effective assessment generally requires developmental history, cross-setting information, evaluation of functional impairment, and consideration of alternative or co-occurring conditions. Care commonly combines psychoeducation, behavioral and family-based interventions, school support, and treatment of comorbid disorders when clinically appropriate.

From Diagnostic Clarification to Coordinated, Measurement-Informed Care

The DMDD landscape has shifted toward clearer differentiation from pediatric bipolar disorder, oppositional defiant disorder, major depressive disorder, attention-deficit/hyperactivity disorder, anxiety disorders, autism spectrum disorder, and trauma-related conditions. These distinctions matter because symptom overlap can contribute to inconsistent diagnosis and treatment selection. Current practice increasingly emphasizes longitudinal observation, validated symptom measures, caregiver and teacher reports, and coordinated plans spanning healthcare, education, and social services. Earlier recognition of persistent irritability is also encouraging interventions before impairment becomes entrenched, while ongoing debate remains about diagnostic boundaries, developmental stability, and the best ways to operationalize severity.

Artificial Intelligence Supports Screening, Coordination, and Evidence Generation

Artificial intelligence may assist DMDD-related care through structured analysis of clinical notes, digital symptom tracking, appointment triage, and identification of changes in irritability or functioning. It can also help organize information from caregivers, teachers, and clinicians, potentially improving longitudinal assessment. However, AI-generated signals are not diagnostic evidence by themselves. Pediatric mental health data can reflect cultural, linguistic, socioeconomic, and access-related biases, and automated tools require transparent validation, privacy safeguards, human oversight, and clear escalation pathways. Responsible use should support-not replace-clinical judgment, family engagement, and developmental assessment.

Regional Insights: Uneven Access Shapes DMDD Recognition and Care

In North America, established child and adolescent mental health systems support diagnostic research and multidisciplinary care, although service fragmentation and long waits remain important barriers. Europe benefits from broad public-health infrastructure, but diagnostic practice, reimbursement, and access vary across countries. Asia-Pacific combines advanced specialist capacity in some settings with substantial unmet need and workforce constraints elsewhere. Latin America faces uneven availability of child psychiatry, behavioral therapy, and school-based services, with urban-rural disparities. The Middle East is expanding mental health capacity while addressing stigma, conflict-related stressors, and shortages of specialists. Africa continues to face limited child mental health resources, requiring integration with primary care, schools, community organizations, and task-sharing models.

Group Insights: Policy Alignment and Health-System Capacity Differ

Across ASEAN, DMDD-related needs are influenced by diverse languages, health systems, and levels of specialist availability, making adaptable school and primary-care pathways important. BRICS countries show substantial variation in pediatric mental health infrastructure, urban access, and community-based provision. The European Union benefits from policy coordination and cross-border knowledge exchange, while implementation remains nationally determined. G7 members generally possess stronger research and specialist networks but still face inequities, workforce shortages, and fragmented services. GCC countries are investing in mental health infrastructure and digital access, with culturally responsive family engagement remaining essential. NATO members span varied systems, but shared attention to child resilience, trauma-informed care, and continuity during crises is relevant.

Country Insights: National Context Determines Diagnostic and Service Pathways

Australia combines specialist services with school and community programs, while rural and remote access remains a challenge. Brazil and Mexico must address regional disparities and uneven access to child mental health professionals. Canada and the United States have substantial clinical and research capacity, yet wait times, insurance or coverage differences, and fragmented care can limit access. China and India face large populations, regional variation, and growing demand for scalable school and primary-care support. Japan and South Korea have advanced healthcare systems, with continuing attention to youth stress, stigma, and service coordination. France, Germany, Italy, Spain, and the United Kingdom provide established public or mixed systems, but referral pathways, workforce capacity, and waiting times differ. Russia’s service environment is shaped by regional variation and the availability of specialized child mental health resources. Across all countries, culturally appropriate assessment and family-centered care are central to reliable diagnosis.

Action Priorities for Leaders: Build Reliable, Equitable Care Pathways

Industry and health-system leaders should establish standardized, developmentally appropriate assessment pathways that use information from multiple settings and explicitly evaluate comorbidities and safety concerns. Strengthening training for pediatricians, primary-care clinicians, educators, and mental health professionals can improve recognition while reducing inappropriate diagnostic substitution. Integrated referral networks should connect families with evidence-based behavioral and parent-focused interventions, school accommodations, and social support. Leaders should also invest in outcome measurement, culturally and linguistically adapted tools, privacy-preserving digital services, and workforce models that extend specialist expertise through supervision and telehealth. AI initiatives should begin with clearly defined clinical use cases, independent validation, bias monitoring, and mandatory clinician review.

Research Methodology: Evidence-Based Synthesis of Clinical and System Context

This executive summary uses the supplied market topic as a clinical-domain reference and synthesizes established diagnostic frameworks, public-health principles, and internationally recognized approaches to child and adolescent mental healthcare. The analysis focuses on condition characteristics, diagnostic differentiation, service delivery, regional access, policy context, and responsible technology use. It does not estimate market size, shares, revenue, or growth. Because country and group-level conditions change over time, local clinical guidelines, regulatory requirements, epidemiological studies, and service-availability data should be reviewed before operational decisions are made.

Conclusion: Earlier Recognition and Coordinated Support Are Central

DMDD care is best understood as a longitudinal, family-centered, and cross-sector challenge rather than a single diagnostic encounter. Progress depends on distinguishing chronic irritability from other developmental and mood presentations, expanding access to evidence-based psychosocial care, and coordinating healthcare, schools, and families. Regional and national differences make adaptable implementation essential. Carefully governed digital tools, including AI, may improve monitoring and coordination, but equitable outcomes will depend on validated methods, strong privacy protections, and sustained human oversight.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Disruptive Mood Dysregulation Disorder Market, by Treatment Type
7.1. Introduction
7.2. Antidepressants
7.3. Antipsychotics
7.4. Cognitive Behavioral Therapy (CBT)
7.5. Mood Stabilizers
7.6. Parent Training Programs
7.7. Stimulants
8. Disruptive Mood Dysregulation Disorder Market, by Care Setting
8.1. Introduction
8.2. Inpatient
8.3. Outpatient
9. Disruptive Mood Dysregulation Disorder Market, by Route Of Administration
9.1. Introduction
9.2. Injectable
9.2.1. Prefilled Syringe
9.2.2. Vial
9.3. Oral
10. Disruptive Mood Dysregulation Disorder Market, by Age Group
10.1. Introduction
10.2. Adolescents (12-17 years)
10.3. Children (6-11 years)
11. Disruptive Mood Dysregulation Disorder Market, by End User
11.1. Introduction
11.2. Digital Health Consumers
11.3. Hospitals
11.4. Mental Health Clinics
11.5. Research Institutes
11.6. Schools & Educational Institutions
12. Disruptive Mood Dysregulation Disorder Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Disruptive Mood Dysregulation Disorder Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Disruptive Mood Dysregulation Disorder Market, by Country
14.1. Introduction
14.2. United States
14.3. Germany
14.4. China
14.5. United Kingdom
14.6. India
14.7. Japan
14.8. Russia
14.9. Brazil
14.10. Canada
14.11. Italy
14.12. Mexico
14.13. France
14.14. Spain
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Ajanta Pharma Inc.
16.2. Aurobindo Pharma Inc.
16.3. Biesterfeld Plastic GmbH
16.4. Cerata Pharmaceuticals LLP
16.5. Cipla Limited
16.6. Dr. Reddy’s Laboratories Ltd.
16.7. Eli Lilly and Company
16.8. Johnson & Johnson Services, Inc.
16.9. Maya Biotech Pvt. Ltd.
16.10. Novartis AG
16.11. Otsuka Pharmaceutical Development & Commercialization, Inc.
16.12. Pfizer Inc.
16.13. Synnat Pharma Private Limited
16.14. Zydus Lifesciences Limited.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Disruptive Mood Dysregulation Disorder Market, Years Considered for the Study
FIGURE 2. Global Disruptive Mood Dysregulation Disorder Market, Research Design
FIGURE 3. Global Disruptive Mood Dysregulation Disorder Market, Research Framework
FIGURE 4. Global Disruptive Mood Dysregulation Disorder Market, Data Triangulation
FIGURE 5. Global Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2025 vs 2032 (%)
FIGURE 7. Global Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2025 vs 2032 (%)
FIGURE 9. Global Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2025 vs 2032 (%)
FIGURE 11. Global Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2025 vs 2032 (%)
FIGURE 13. Global Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Disruptive Mood Dysregulation Disorder Market Size, by End User, 2025 vs 2032 (%)
FIGURE 15. Global Disruptive Mood Dysregulation Disorder Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Disruptive Mood Dysregulation Disorder Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Disruptive Mood Dysregulation Disorder Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Disruptive Mood Dysregulation Disorder Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Disruptive Mood Dysregulation Disorder Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Disruptive Mood Dysregulation Disorder Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Disruptive Mood Dysregulation Disorder Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Disruptive Mood Dysregulation Disorder Market Segmentation & Coverage
TABLE 2. Global Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
TABLE 3. Global Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 4. Global Antidepressants Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Antidepressants Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Antidepressants Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Antipsychotics Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Antipsychotics Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Antipsychotics Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Cognitive Behavioral Therapy (CBT) Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Cognitive Behavioral Therapy (CBT) Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Cognitive Behavioral Therapy (CBT) Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Mood Stabilizers Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Mood Stabilizers Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Mood Stabilizers Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Parent Training Programs Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Parent Training Programs Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Parent Training Programs Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Stimulants Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Stimulants Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Stimulants Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 23. Global Inpatient Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Inpatient Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Inpatient Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Outpatient Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Outpatient Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Outpatient Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 30. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Prefilled Syringe Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Prefilled Syringe Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Prefilled Syringe Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Vial Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Vial Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Vial Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 43. Global Adolescents (12-17 years) Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Adolescents (12-17 years) Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Adolescents (12-17 years) Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Children (6-11 years) Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Children (6-11 years) Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Children (6-11 years) Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 50. Global Digital Health Consumers Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Digital Health Consumers Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Digital Health Consumers Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Mental Health Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Mental Health Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Mental Health Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Schools & Educational Institutions Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Schools & Educational Institutions Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Schools & Educational Institutions Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Disruptive Mood Dysregulation Disorder Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Asia-Pacific Disruptive Mood Dysregulation Disorder Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Asia-Pacific Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 68. Asia-Pacific Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 69. Asia-Pacific Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 70. Asia-Pacific Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 71. Asia-Pacific Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 72. Asia-Pacific Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 73. North America Disruptive Mood Dysregulation Disorder Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. North America Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 75. North America Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 76. North America Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 77. North America Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 78. North America Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 79. North America Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 80. Latin America Disruptive Mood Dysregulation Disorder Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Latin America Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 82. Latin America Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 83. Latin America Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 84. Latin America Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 85. Latin America Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 86. Latin America Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. Europe Disruptive Mood Dysregulation Disorder Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Europe Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 89. Europe Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 90. Europe Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 91. Europe Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 92. Europe Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 93. Europe Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 94. Middle East Disruptive Mood Dysregulation Disorder Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Middle East Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 96. Middle East Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 97. Middle East Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 98. Middle East Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 99. Middle East Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 100. Middle East Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 101. Africa Disruptive Mood Dysregulation Disorder Market Size, by Region, 2017-2032 (USD Million)
TABLE 102. Africa Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 103. Africa Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 104. Africa Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 105. Africa Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 106. Africa Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 107. Africa Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 108. Global Disruptive Mood Dysregulation Disorder Market Size, by Group, 2017-2032 (USD Million)
TABLE 109. ASEAN Disruptive Mood Dysregulation Disorder Market Size, by Group, 2017-2032 (USD Million)
TABLE 110. ASEAN Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 111. ASEAN Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 112. ASEAN Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 113. ASEAN Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 114. ASEAN Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 115. ASEAN Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. GCC Disruptive Mood Dysregulation Disorder Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. GCC Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 118. GCC Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 119. GCC Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 120. GCC Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 121. GCC Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 122. GCC Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 123. European Union Disruptive Mood Dysregulation Disorder Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. European Union Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 125. European Union Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 126. European Union Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 127. European Union Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 128. European Union Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 129. European Union Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. BRICS Disruptive Mood Dysregulation Disorder Market Size, by Group, 2017-2032 (USD Million)
TABLE 131. BRICS Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 132. BRICS Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 133. BRICS Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 134. BRICS Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 135. BRICS Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 136. BRICS Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 137. G7 Disruptive Mood Dysregulation Disorder Market Size, by Group, 2017-2032 (USD Million)
TABLE 138. G7 Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 139. G7 Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 140. G7 Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 141. G7 Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 142. G7 Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 143. G7 Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 144. NATO Disruptive Mood Dysregulation Disorder Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. NATO Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 146. NATO Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 147. NATO Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 148. NATO Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 149. NATO Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 150. NATO Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 151. Global Disruptive Mood Dysregulation Disorder Market Size, by Country, 2017-2032 (USD Million)
TABLE 152. United States Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
TABLE 153. United States Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 154. United States Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 155. United States Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 156. United States Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 157. United States Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 158. United States Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. Germany Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
TABLE 160. Germany Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 161. Germany Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 162. Germany Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 163. Germany Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 164. Germany Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 165. Germany Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 166. China Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
TABLE 167. China Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 168. China Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 169. China Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 170. China Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 171. China Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 172. China Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 173. United Kingdom Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
TABLE 174. United Kingdom Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 175. United Kingdom Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 176. United Kingdom Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 177. United Kingdom Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 178. United Kingdom Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 179. United Kingdom Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 180. India Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
TABLE 181. India Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 182. India Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 183. India Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 184. India Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 185. India Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 186. India Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 187. Japan Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
TABLE 188. Japan Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 189. Japan Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 190. Japan Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 191. Japan Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 192. Japan Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 193. Japan Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 194. Russia Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
TABLE 195. Russia Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 196. Russia Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 197. Russia Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 198. Russia Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 199. Russia Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 200. Russia Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. Brazil Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
TABLE 202. Brazil Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 203. Brazil Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 204. Brazil Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 205. Brazil Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 206. Brazil Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 207. Brazil Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. Canada Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
TABLE 209. Canada Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 210. Canada Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 211. Canada Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 212. Canada Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 213. Canada Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 214. Canada Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 215. Italy Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
TABLE 216. Italy Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 217. Italy Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 218. Italy Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 219. Italy Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 220. Italy Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 221. Italy Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 222. Mexico Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
TABLE 223. Mexico Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 224. Mexico Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 225. Mexico Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 226. Mexico Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 227. Mexico Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 228. Mexico Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 229. France Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
TABLE 230. France Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 231. France Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 232. France Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 233. France Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 234. France Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 235. France Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 236. Spain Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
TABLE 237. Spain Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 238. Spain Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 239. Spain Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 240. Spain Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 241. Spain Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 242. Spain Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 243. Australia Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
TABLE 244. Australia Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 245. Australia Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 246. Australia Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 247. Australia Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 248. Australia Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 249. Australia Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 250. South Korea Disruptive Mood Dysregulation Disorder Market Size, 2017-2032 (USD Million)
TABLE 251. South Korea Disruptive Mood Dysregulation Disorder Market Size, by Treatment Type, 2017-2032 (USD Million)
TABLE 252. South Korea Disruptive Mood Dysregulation Disorder Market Size, by Care Setting, 2017-2032 (USD Million)
TABLE 253. South Korea Disruptive Mood Dysregulation Disorder Market Size, by Route Of Administration, 2017-2032 (USD Million)
TABLE 254. South Korea Disruptive Mood Dysregulation Disorder Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 255. South Korea Disruptive Mood Dysregulation Disorder Market Size, by Age Group, 2017-2032 (USD Million)
TABLE 256. South Korea Disruptive Mood Dysregulation Disorder Market Size, by End User, 2017-2032 (USD Million)
TABLE 257. Global Disruptive Mood Dysregulation Disorder Market Share, by Key Player, 2025
TABLE 258. Global Disruptive Mood Dysregulation Disorder Market, Key Experts

Companies Mentioned

  • Ajanta Pharma Inc.
  • Aurobindo Pharma Inc.
  • Biesterfeld Plastic GmbH
  • Cerata Pharmaceuticals LLP
  • Cipla Limited
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Maya Biotech Pvt. Ltd.
  • Novartis AG
  • Otsuka Pharmaceutical Development & Commercialization, Inc.
  • Pfizer Inc.
  • Synnat Pharma Private Limited
  • Zydus Lifesciences Limited.

Related Topics

Related Reports

Bipolar Disorder Therapeutics Market - Global Forecast 2026-2032 - Product Image

Bipolar Disorder Therapeutics Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Seasonal Affective Disorder Medications Market Summary: Industry Trends and Forecast - Product Image

Seasonal Affective Disorder Medications Market Summary: Industry Trends and Forecast

  • Report
  • 98 Pages
  • Global
From
Bipolar Disorder Drugs and Treatment Market Report 2026 - Product Image

Bipolar Disorder Drugs and Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Bipolar Disorder Therapeutics - Global Strategic Business Report - Product Image

Bipolar Disorder Therapeutics - Global Strategic Business Report

  • Report
  • 380 Pages
  • Global
From
Postpartum Depression Market Report 2026 - Product Image

Postpartum Depression Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.